Despite the competitive threat posed by Eli Lilly’s acquisition of Scorpion Therapeutics’ STX-478, which has shown promising efficacy in several cancer types, Relay Therapeutics’ RLY-2608 ...

By pole configuration, the market from the DPDT segment is the fastest growing, with an expected CAGR of 7.3% between 2024 and 2032. DPDT relays are favored for their ability to control two separate ...